New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG
Summary
Todays announcement comes on the heels of New Day Diagnostics’ recent merger with EDP Biotech Corp. and furthers the company’s mission of expanding the availability of cost-effective early-detection products to patients. The addition of Epi proColon expands the company portfolio to include a much needed non-invasive CRC screening test that is both affordable and convenient,” said Eric Mayer, CEO of New Day Diagnostics LLC. This, coupled with an increased likelihood of reimbursement by CMS, would allow the company to make an important contribution to reducing cancer disease and deaths. The company is a Contract Research Organization (CRO) with the capabilities for support throughout the diagnostic process, from biomarker to discovery to product launch. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics developed blood tests for various cancer indications with high unmet medical needs.